Rodrigo DeAntonio

Employment

• Cevaxin Executive and Scientific Director
  2018 - Present
• GlaxoSmithKline Plc Epidemiology and Health Outcomes Director LATAM
  2009 - 2018

Education

• Instituto Nacional de Salud Pública Dr. PH
  2014 - 2018
• Universitat Pompeu Fabra Master in Health Economics
  2005 - 2007
• Universidad Del Rosario Degree in Epidemiology
  2003 - 2005
• Universidad Del Rosario Medical Doctor
  1994 - 2000

Projects & Funding

Projects & funding information is unavailable.

Publications (94)

• Recent Advances in Dengue Vaccines for Children: Current Evidence and Future Directions
  Pediatric Infectious Disease Journal 2026 DOI: 10.1097/INF.0000000000005172
  +Save
• Behavioral pattern analysis for adherence in clinical trials using sequence mining
  Computers in Biology and Medicine 2026 DOI: 10.1016/j.compbiomed.2026.111607
  +Save
• A Comparative Analysis of National Health Strategies and Policy Documents in Selected Latin American and African Countries
  International Journal of Environmental Research and Public Health 2026 DOI: 10.3390/ijerph23080986
  +Save
• TAK-003: development of a tetravalent dengue vaccine
  Expert Review of Vaccines 2025 DOI: 10.1080/14760584.2025.2490295
  +Save
• The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama
  Expert Review of Pharmacoeconomics & Outcomes Research 2025 DOI: 10.1080/14737167.2025.2514530
  +Save
• Effectiveness of pneumococcal conjugate 13-valent vaccine against severe pneumonia in Panama: a matched case-control study
  Jornal de Pediatria 2025 DOI: 10.1016/j.jped.2025.03.008
  +Save
• Dynamics of Innate Immunity in SARS-CoV-2 Infections: Exploring the Impact of Natural Killer Cells, Inflammatory Responses, Viral Evasion Strategies, and Severity
  Cells 2025 DOI: 10.3390/cells14110763
  +Save
• Identifying Gaps and Opportunities for Maternal and Neonatal Immunization Research and Implementation in Latin America
  Pediatric Infectious Disease Journal 2025 DOI: 10.1097/INF.0000000000004693
  +Save
• Nosocomial RSV-related In-hospital Mortality in Children <5 Years: A Global Case Series
  Pediatric Infectious Disease Journal 2023 DOI: 10.1097/inf.0000000000003747
  +Save
• Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial
  Human Vaccines & Immunotherapeutics 2023 DOI: 10.1080/21645515.2023.2204787
  +Save